{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+%28Advanced%2FMetastatic%29&page=3", "query": { "condition": "Breast Cancer (Advanced/Metastatic)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 814, "total_pages": 82, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+%28Advanced%2FMetastatic%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+%28Advanced%2FMetastatic%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:36:46.993Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01526473", "title": "A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2+ Cancer" ], "interventions": [ { "name": "AVX901", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Kim Lyerly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-02", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526473" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT02312622", "title": "Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Non-small Cell Lung Cancer (NSCLC)", "Recurrent Non-small Cell Lung Cancer (NSCLC)", "Extensive-stage Small Cell Lung Cancer (SCLC)", "Recurrent Small Cell Lung Cancer (SCLC)", "Tumors Metastatic to Brain", "Metastatic Breast Cancer (mBC)" ], "interventions": [ { "name": "Pegylated Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joel Neal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2015-08", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02312622" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" }, { "nct_id": "NCT05933265", "title": "Study of LP-184 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "GBM", "TNBC - Triple-Negative Breast Cancer", "NSCLC", "Pancreatic Adenocarcinoma", "DDR Gene Mutation" ], "interventions": [ { "name": "LP-184", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nivolumab & Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantern Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2023-06-09", "completion_date": "2026-07-28", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 7, "location_summary": "Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05933265" }, { "nct_id": "NCT00379509", "title": "Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "TdT-mediated dUTP nick end labeling assay", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2006-04", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379509" }, { "nct_id": "NCT00496366", "title": "Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2/Neu-positive Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2007-07-23", "completion_date": "2017-03-20", "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 2, "location_summary": "Hamilton, New Jersey • New Brunswick, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496366" }, { "nct_id": "NCT00722072", "title": "Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "fulvestrant", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 12, "start_date": "2008-07", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2018-02-26", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722072" }, { "nct_id": "NCT02706392", "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "ROR1 CAR-specific Autologous T-Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2016-03-16", "completion_date": "2021-09-28", "has_results": true, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706392" }, { "nct_id": "NCT07227233", "title": "Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.", "type": "DRUG" }, { "name": "Treatment of physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2026-03-31", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-14T09:36:46.993Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227233" } ] }